Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer

ConclusionsWe revealed that palbociclib and MLN0128 had synergistic anti-cancer activity in both pRb + ER-negative cell lines and a TNBC PDX model. Our results indicate that such combination therapy is worthy of further investigation in a clinical setting.

http://link.springer.com/10.1007/s10549-018-05104-9

Source: Breast Cancer Research and Treatment - January 3, 2019 Category: Cancer & Oncology Source Type: research